Tempus AI

Tempus AI EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Tempus AI (TEM) as of Nov 20, 2026 is -39.25. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -12.86 — a change of 205.12% (lower).

EV/EBITDA

-39.25

YoY

205.12%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Tempus AI is 2025 -39.25 . EV/EBITDA (Enterprise Value to EBITDA) of Tempus AI was 2024 -12.86 . It decreases by 205.12% lower compared to the previous year.

The Tempus AI EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2019
-73.66 USD
Jan 1, 2020
-45.06 USD
Jan 1, 2021
-36.53 USD
Jan 1, 2022
-34.42 USD
Jan 1, 2023
-47.95 USD
Jan 1, 2024
-12.86 USD
Jan 1, 2025
-39.25 USD
The Tempus AI EV/EBITDA history
YEAREV/EBITDAYoY
-39.25+205.12%
-12.86-73.17%
-47.95+39.32%
-34.42-5.78%
-36.53-18.92%
-45.06-38.83%
-73.66—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

EV/EBITDA (Enterprise Value to EBITDA) of Tempus AI is -39.25 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Tempus AI changed from -12.86 to -39.25, representing a 205.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Tempus AI since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Tempus AI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Tempus AI

All Key Metrics — Tempus AI